Given the current short-term trend, the stock is expected to rise 2.94 during the next 3 months and, with a 90 probability hold a price between 31.16 and 41.52 at the end of this 3-month period. Get the latest Rapt Therapeutics RAPT detailed stock quotes, stock data, Real-Time ECN, charts. This means that this stock is suited as a new addition to your portfolio as trading bullish markets is always a lot easier. The stock lies in the middle of a very wide and weak rising trend in the short term and a further rise within the trend is signaled. View Rapt Therapeutics RAPT investment & stock information. Third quarter 2021 earnings released: US0.63 loss per. This means that if you invested $100 now, your current investment may be worth 186.023$ on 2022 December 30, Friday. RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. These predictions take several variables into account such as volume changes, price changes, market cycles, similar stocks.įuture price of the stock is predicted at 66.84733106897$ ( 86.023% ) after a year according to our prediction system. Our site uses a custom algorithm based on Deep Learning that helps our users to decide if RAPT could be a good portfolio addition.
RAPT Therapeutics stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. stock forecastĪs of 2021 December 30, Thursday current price of RAPT stock is 35.935$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception). The company was founded in 2015 and is headquartered in South San Francisco, CA.
Our cutting-edge science is fully focused on developing oral therapeutics that intelligently target key drivers of the immune system to transform the treatment of cancer and inflammation, and improve and empower countless lives. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases. RAPT Therapeutics is a clinical-stage biopharmaceutical company driven by a bold missionto conquer cancer and inflammatory disease in our lifetime. The Company is also pursuing a range of targets that are in the discovery stage of development.1 year RAPT Therapeutics Forecast: 66.84733106897 *ĥ year RAPT Therapeutics Forecast: 293.560 * About the Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Since coming public at 12.00, on 10/31/19 Rapt Therapeutics ( RAPT ) has been under accumulation, with the stock has rising to 42,and now after a recent triangle breakout, trading above 30 This company out of San Francisco,Ca is working on genetic cancer cure drugs.